ArticleBMC public health2025
Assessing immunization coverage in Southern togo: implications for perennial malaria chemoprevention delivery.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMalaria remains a major health challenge in sub-Saharan Africa, especially for children under five. The World Health Organization (WHO) recommends perennial malaria chemoprevention (PMC) to children in areas of medium to high perennial transmission. In Togo, since 2022, a pilot project has leveraged the Expanded Program on Immunization (EPI) to deliver PMC to children under two years; however, the extent to which PMC achieves its desired outcome may depend on EPI performance. This study assessed EPI coverage and factors associated with zero-dose status in southern Togo.
methodsWe used secondary data from a multi-stage sampling household survey on malaria prevalence conducted in the Haho district in 2022, focusing on children aged 12-23 months. Vaccination history was obtained via EPI cards or caretaker recall. Immunization coverage was defined according to the WHO criteria. Factors associated with zero-dose, defined as the absence of the first diphtheria-tetanus-pertussis-containing vaccine, were assessed using mixed-effects multivariable logistic regression models. Potential risk factors included caretaker and household characteristics, vaccination perceptions, and geographic access. Sensitivity analyses were performed to validate caretaker-reported data.
resultsAmong 583 children, 60.7% were fully immunized, and 15.8% were classified as zero-dose. Key barriers for vaccination included family discouragement (17.4%), lack of time (15.1%), and COVID-19-related issues (14%). Vaccine uptake declined with age, from 84% at birth to 35% for the second measles vaccine at 15 months. Zero-dose status was significantly associated with low caregiver education (adjusted odds ratio [aOR] 5.02, 95% confidence interval [CI] 1.85-13.60), negative attitudes toward vaccination safety (aOR 8.60, 95% CI 3.32-22.30), and lack of reliance on modern healthcare (aOR 3.06, 95% CI 1.26-7.48). Access to the nearest health facility, whether measured by distance (P = 0.86) or time (P = 0.11), showed no significant association.
conclusionThe suboptimal immunization coverage and a high proportion of zero-dose children highlight the need to strengthen community engagement to improve vaccination awareness and ensure the effective and equitable delivery of PMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.